BMO Capital Maintains Market Perform on Mirati Therapeutics, Raises Price Target to $72
Portfolio Pulse from Benzinga Newsdesk
BMO Capital analyst Evan David Seigerman has maintained a 'Market Perform' rating on Mirati Therapeutics (NASDAQ:MRTX) and raised the price target from $31 to $72.
October 06, 2023 | 12:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BMO Capital has maintained a 'Market Perform' rating on Mirati Therapeutics and raised the price target from $31 to $72.
The raised price target by BMO Capital indicates a positive outlook for Mirati Therapeutics. This could potentially lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100